EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes

Hanzhou Li iD, John Moon, Nathan Sim, Michal Horný, Nicholas Lima iD, Menelaos Konstantinidis, Deepak Iyer, Sonia Benenati, Judy Gichoya, Janice Newsome, Zachary Bercu

Cancer Medicine · 2025

DOI: 10.1002/cam4.71418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hanzhou Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Imaging Sciences, Emory School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Patient Discharge, Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Harvey L. Neiman Health Policy Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Post‐embolization syndrome after transarterial chemoembolization (TACE) and Yttrium‐90 radioembolization (TARE) causes significant morbidity. Understanding whether discharge prescriptions influence short‐term outcomes may guide standardized pain‐management strategies.

Methods

A retrospective cohort study of 3191 patients (3988 procedures) with hepatocellular carcinoma from the Merative MarketScan Databases (2009–2022) was performed. The composite outcome was 7‐day drug escalation or hospital readmission. Bivariate logistic regression identified candidate variables ( p < 0.10); multivariable logistic regression with patient‐clustered robust standard errors estimated adjusted odds ratios (aORs), adjusting for age, sex, and Charlson Comorbidity Index (CCI).

Results

Compared to patients discharged without opioids post‐chemoembolization, those prescribed opioids at discharge had 83% lower odds of experiencing drug escalation or readmission (odds ratio [aOR] = 0.17, p < 0.001), and those undergoing radioembolization had 59% lower odds (aOR = 0.41, p < 0.001). Being prescribed antiemetics or steroids was also associated with lower odds of escalation/readmission events, with percentages varying by procedure type.

Conclusions

Prescribing opioids, along with antiemetics and steroids, at discharge may reduce the likelihood of post‐procedural events, such as drug escalation and readmission, in patients undergoing trans‐arterial chemoembolization and radioembolization for hepatocellular carcinoma. These findings highlight the importance of a comprehensive pain management strategy in interventional oncology and warrant consideration in clinical practice guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient DischargeCarcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticAnalgesics, OpioidHumansFemaleMaleMiddle AgedRetrospective StudiesAgedPatient ReadmissionYttrium RadioisotopesAntiemetics

Stichwörter der Autor:innen

chemoembolizationhepatocellular carcinomaopioidspost‐embolization syndromeradioembolizationreadmission

Substanzen

Analgesics, OpioidYttrium RadioisotopesAntiemeticsYttrium-90

Autor:innen und Institutionen

  • Department of Radiology and Imaging Sciences, Emory School of Medicine, Atlanta, Georgia, USA.
  • Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, Amherst, Massachusetts, USA.
  • Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • University of Toronto, Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada.
  • Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

ORCID-Profile: Hanzhou Li, Nicholas Lima

Förderung

  • Harvey L. Neiman Health Policy Institute

Zitieren

APA

Li, H., Moon, J., Sim, N., Horný, M., Lima, N., Konstantinidis, M., Iyer, D., Benenati, S., Gichoya, J., Newsome, J., & Bercu, Z. (2025). Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes. Cancer Medicine. https://doi.org/10.1002/cam4.71418

Vancouver

Li H, Moon J, Sim N, Horný M, Lima N, Konstantinidis M, et al. Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes. Cancer Medicine. 2025. doi:10.1002/cam4.71418

BibTeX
@article{Li2025,
  author = {Li, Hanzhou and Moon, John and Sim, Nathan and Horný, Michal and Lima, Nicholas and Konstantinidis, Menelaos and Iyer, Deepak and Benenati, Sonia and Gichoya, Judy and Newsome, Janice and Bercu, Zachary},
  title = {Association Between Discharge Medications and Oncologic Post‐Embolization‐Syndrome‐Related Outcomes},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71418}
}
Kostenlos starten →